GCGR
ENSG00000215644
Target class
GPCR
Chromosome
17
Approved drugs
3
Clinical candidates (approved and in development)
15
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 15
- Chemical probe available
- Yes
- Other names
- GGR
- Target name
- GCGR
- Gene name
- Glucagon receptor
- Gene symbol
- GCGR
- Protein name
- Glucagon receptor (GL-R)
- Gene biotype
- Protein coding
- Gene family
- Glucagon receptor family
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 8
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 110.89
- Tissue specificity (Gini)
- 0.925
- Tissue specificity (tau)
- 0.979
- KEGG gene identifiers
- hsa:2642
- Protein interaction confidence
- 0.838786
- Protein interaction partners
- 14
- R-HSA-163359
- R-HSA-416476
- R-HSA-418555
- R-HSA-420092
- End position
- 81814023
- Start position
- 81803105
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Note=Is rapidly internalized after ligand-binding. .
- PubMed 19657311
- PubMed 23863937
- PubMed 27111510
- PubMed 28514451
- PubMed 30294546
- PubMed 32677665
- PubMed 7507321
- PubMed 9287038
- Tissue specificity (tau)
- 0.978627
- Expression inequality (Gini)
- 0.925345
Expression in transcripts per million
- Liver
- 110.89
- Kidney - Medulla
- 70.47
- Kidney - Cortex
- 25.78
- Nerve - Tibial
- 12.86
- Skin - Not Sun Exposed (Suprapubic)
- 2.23
Expression in transcripts per million
- Liver110.89
- Kidney - Medulla70.47
- Kidney - Cortex25.78
- Nerve - Tibial12.86
- Skin - Not Sun Exposed (Suprapubic)2.23
- Testis2.23
- Skin - Sun Exposed (Lower leg)1.51
- Colon - Sigmoid1.32
- Vagina0.82
- Colon - Transverse0.8
- Small Intestine - Terminal Ileum0.79
- Pancreas0.76
- Fallopian Tube0.58
- Cervix - Ectocervix0.52
- Cells - EBV-transformed lymphocytes0.48
- Pituitary0.45
- Cervix - Endocervix0.37
- Esophagus - Gastroesophageal Junction0.25
- Artery - Coronary0.23
- Prostate0.23
- Esophagus - Mucosa0.23
- Adipose - Subcutaneous0.23
- Bladder0.22
- Esophagus - Muscularis0.19
- Uterus0.17
And 29 more, listed on the interactive page.
- GO:0006091
- GO:0007188
- GO:0007189
- GO:0007584
- GO:0008217
- GO:0071377
- GO:0005886
- GO:0016020
- GO:0004967
- GO:0005085
- GO:0005515
Related records
Trials (242)
- A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
- A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)
- A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
- A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
- A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
- A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers
- A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
- A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382
- A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
- A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
- A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
- A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
- A Study for Participants With Type 2 Diabetes Mellitus
- A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
Drugs (15)
- Adomeglivant Glucagon receptor antagonist
- Cotadutide Glucagon receptor agonist
- Crotedumab Glucagon receptor inhibitor
- Dasiglucagon Glucagon receptor agonist
- Dasiglucagon hydrochloride Glucagon receptor agonist
- Efinopegdutide Glucagon receptor agonist
- Glucagon Glucagon receptor agonist
- Glucagon hydrochloride Glucagon receptor agonist
- MK-0893 Glucagon receptor antagonist
- MK-3577 Glucagon receptor antagonist
- PF-06291874 Glucagon receptor antagonist
- Retatrutide Glucagon receptor agonist
- SAR425899 Glucagon receptor agonist
- Survodutide Glucagon receptor agonist
- Volagidemab Glucagon receptor inhibitor